Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Advanced prostate cancer frequently metastasizes and resists conventional treatments.
• Prostate apoptosis response-4 protein (Par-4) is a tumor suppressor inducing apoptosis in resistant cancer cells.
• Par-4 targets cancer cells by binding to Glucose-regulated protein-78 (GRP78) on their surface.

Purpose of the Study:

• To investigate 3-Arylquinolines (arylquins) as agents to induce Par-4 secretion.
• To identify arylquin structures that promote Par-4 secretion and avoid off-target effects.
• To elucidate the mechanism of Par-4 release from vimentin by arylquins.

Main Methods:

• Structure-activity relationship studies of arylquins.
• [(3)H]-dofetilide binding assays to evaluate hERG potassium channel activity.
• Fluorescence-based binding studies using purified vimentin rod domain (residues 99-411).

Main Results:

• Identified specific arylquins that effectively promote Par-4 secretion.
• Characterized structural features of arylquins that separate Par-4 secretion from hERG channel binding.
• Binding studies suggest arylquins interact with multiple sites within the vimentin rod domain to release Par-4.

Conclusions:

• Arylquins represent a promising class of compounds for inducing paracrine Par-4 secretion.
• This approach offers a potential therapeutic strategy for therapy-resistant prostate cancer.
• Understanding the arylquin-vimentin interaction mechanism is key for further drug development.